BMS Expands Manufacturing Agreement With Samsung BioLogics
Bristol-Myers Squibb and Samsung BioLogics announced that the companies have agreed to expand their existing manufacturing agreement. Samsung BioLogics will now manufacture commercial drug substances and drug products at its Incheon manufacturing site for a number of Bristol-Myers Squibb biologic medicines.
Lou Schmukler, president of Global Manufacturing & Supply at Bristol Myers Squibb, said, “Biologic medicines that treat serious diseases are an integral part of Bristol-Myers Squibb’s specialty care portfolio and R&D pipeline. The expanded relationship with Samsung will increase our biologics manufacturing capability and give us the flexibility to respond to increased demand in order to meet the global needs of patients.”
Biologics include a wide array of products such as blood and blood components, vaccines, allergenics, somatic cells, tissues, gene therapy, and recombinant therapeutic proteins.
Dr. TH Kim, president and CEO of Samsung BioLogics, said, “Samsung is delighted to reach the second manufacturing agreement with Bristol-Myers Squibb and we look forward to delivering top quality GMP production. It represents another significant step for Samsung and Bristol-Myers Squibb in strengthening our biopharmaceutical manufacturing relationship.”
Samsung BioLogics is a global full-service provider of quality-driven contract process development and cGMP manufacturing to the global biopharma industry. The company offers process development, drug substance manufacturing, and drug product fill and finish services at its one-stop location.
SB recently entered into a long term manufacturing agreement with Roche under which it will manufacture Roche’s commercial biologic medicines. The company is currently building a second facility, expected to be finished early next year, in addition to its current biologics manufacturing facility in Incheon, Korea.
BMS and Samsung announced their first manufacturing agreement in July 2013, when the companies collaborated to produce a single commercial antibody cancer drug substance. Financial terms of the new agreement have not been disclosed by either company.